Meloxicam Tablets, USP, 15 mg, 1000 Tablets per bottle recall — FDA D-0190-2024
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Browse the newest complete recall records currently stored from FDA enforcement reports and NHTSA vehicle campaigns. “Latest” refers to the newest source-dated record in this database, not the timestamp of our last API check.
The newest recall records with useful source details are listed here.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Marketed without an approved NDA/ANDA: Magnum XXL found to contain undeclared active pharmaceutical ingredient (API) - Sildenafil.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification
Chemical contamination: Presence of benzene
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Marketed Without an Approved NDA/ANDA: FDA analysis found the product to be tainted with Sildenafil an ingredient found in an FDA approved product for the treatment of male sexual…
Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.
Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.
Chemical contamination: Presence of benzene
Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.
Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.
Kia America, Inc. (Kia) is recalling certain 2023 Soul and 2024 Seltos vehicles. Due to a manufacturing error, the side curtain air bags may deploy unexpectedly.
Browse recent months with enough recall history for useful comparison.